| Trial ID: | L4455 |
| Source ID: | NCT01865318
|
| Associated Drug: |
Insulin Degludec
|
| Title: |
Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: insulin degludec
|
| Outcome Measures: |
Primary: Area under the glucose infusion rate curve, 0-24 hours after dosing | Secondary: Maximum glucose infusion rate (GIRmax), 0-24 hours after dosing|Time to maximum glucose infusion rate (tGIRmax), 0-24 hours after dosing|Area under the serum insulin degludec curve, 0-96 hours after dosing
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
MALE
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
36
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-09
|
| Completion Date: |
2007-01
|
| Results First Posted: |
|
| Last Update Posted: |
2015-10-22
|
| Locations: |
Neuss, 41460, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT01865318
|
